Tag: Biotech and Pharma

Novo Nordisk rose as much as 4% after England’s drug price watchdog recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes, marking the first GLP-1 backed for this use in the country.

Eli Lilly has agreed to buy clinical-stage company Centessa Pharmaceuticals for an initial payment of about $6.3 billion in a deal that expands the drugmaker’s neuroscience portfolio and capabilities into sleep medicine.

Novo Nordisk will launch a discounted subscription plan for U.S. Wegovy patients paying for the drug themselves, offering monthly ‌prices up to nearly 30% below its standard rate as it tries to widen access and regain ground from Eli Lilly in the booming obesity-drug market.

Novartis is planning to buy U.S.-based biotech Excellergy for up to $2 billion, betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.

Merck to pay a 6% premium to buy the outstanding shares of Terns Pharmaceuticals, which is developing an oral treatment for leukemia.

Ισχυρή επίδοση κατέγραψε η Lavipharm το 2025 σύμφωνα με τα μη ελεγμένα χρηματοοικονομικά στοιχεία που δημοσιοποίησε η εταιρεία.

Compounded weight-loss drugs that contain vitamin B12 and the main ingredient in Eli Lilly’s (LLY) ‌Zepbound could present health risks to consumers due to a previously unidentified impurity caused in the preparation, the U.S. drugmaker said in a public letter released on Thursday.

Novo Nordisk A/S plans to sell its weight-loss drugs on Hims & Hers Health Inc.’s platform, according to a person familiar with the matter, ending a highly public feud between the two companies that spiraled into a legal battle last month.

Novartis said on Wednesday it intends to build a radioligand therapy manufacturing site in Texas, ‌expanding its U.S. footprint with what will be ‌its first such facility in the state and fifth nationwide.

GSK (GSK) has agreed to pay $950 million in cash for Canadian biotech 35Pharma, it said on Wednesday, marking the second major deal new CEO Luke Miels has struck to accelerate development of new medicines at the British drugmaker.

Fresenius Medical Care AG (FMS) reported fourth-quarter adjusted earnings per share of EUR 1.44, beating expectations.

Hims & Hers Health (HIMS) stock fell after the telehealth company posted mixed quarterly results and issued a weak outlook for the current quarter.

Novo’s drug, CagriSema, didn’t achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly’s rival drug tirzepatide.

Gilead Sciences agrees to acquire biotech company Arcellx for $7.8 billion.

Shares of Moderna (MRNA) slipped Friday after the drugmaker reported better-than-expected quarterly results.

Gilead Sciences (GILD) reported its fourth-quarter and full-year 2025 financial results on February 10, 2026, highlighting strong performance in its base business despite competitive pressures in certain segments. The company’s stock declined 0.94% in aftermarket trading to $150.26, despite exceeding analyst expectations for both revenue and earnings.

AstraZeneca PLC’s (AZN) full-year results showed the pharmaceutical group navigating a challenging comparison period with a robust operational performance and a renewed commitment to long-term growth, analysts said.

Eli Lilly (LLY) will buy therapy developer Orna Therapeutics for up to $2.4 billion in cash, the companies said on Monday.

Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker’s new Wegovy obesity pill and injections in the U.S.

Biogen Inc. forecast 2026 profit above Wall Street’s expectations, signaling that steep cost-cutting measures are cushioning the impact of shrinking sales from its multiple sclerosis franchise.